1 **Title Page**

- 2 Title: Polymethylation Scores for Prenatal Maternal Smoke Exposure Persist Until Age 15 and
- 3 Are Detected in Saliva
- Authors: Freida A. Blostein¹, Jonah Fisher², John Dou¹, Lisa Schenper³, Erin B. Ware² Daniel 4
- 5 A. Notterman³*, Colter Mitchell²*, Kelly M. Bakulski¹*⁺

6 **Affiliations:**

- 7 ¹Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor,
- 8 Michigan, United States of America
- 9 ²Institute for Social Research, University of Michigan, Ann Arbor, Michigan, United States of
- 10 America
- 11 ³Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States
- 12 of America
- 13 *Co-senior authors
- 14 ⁺Corresponding author: bakulski@umich.edu 1415 Washington Heights, Ann Arbor, MI, 48109

15 Abstract

- 16 Background: Prenatal maternal smoking has negative implications for child health. DNA
- 17 methylation signatures can function as biomarkers of prenatal maternal smoking. However little
- 18 work has assessed how DNA methylation signatures of prenatal maternal smoking vary across
- 19 ages, ancestry groups, or tissues. In the Fragile Families and Child Wellbeing study, we tested

whether prenatal maternal smoking was associated with salivary polymethylation scores for
smoking in participants. We assessed the associations' consistency at ages 9 and 15, their
portability across participants from African, European, and Hispanic genetic ancestries and the
accuracy of exposure classification using area under the curve (AUC) from receiver operating
curve analyses.

25 **Results**: We created saliva polymethylation scores using coefficients from a meta-analysis of 26 prenatal maternal smoke exposure and DNA methylation in newborn cord blood. In the full 27 sample at age 9 (n=753), prenatal maternal smoke exposure was associated with a 0.52 (95% CI: 28 0.36, 0.67) standard deviation higher polymethylation score for prenatal smoke exposure. The 29 direction of the association was consistent when stratified by genetic ancestries. In the full 30 sample at age 15 (n=746), prenatal maternal smoke exposure was associated with a 0.46 (95% CI: 31 0.3, 0.62) standard deviation higher polymethylation score for prenatal smoke exposure, and the 32 effect size was attenuated among the European and Hispanic genetic ancestry samples. The 33 polymethylation score was reasonably accurate at classifying prenatal maternal smoke exposure 34 (AUC age 9=0.78, P value comparing to base model<0.001, age 15=0.77, P value comparing to 35 base model < 0.001). The polymethylation score showed higher classification accuracy than using 36 a single *a priori* site in the AHRR gene (cg05575921 AUC=0.74, P value comparing to 37 polymethylation score=0.03; age 15=0.73, P value comparing to polymethylation score=0.01). 38 **Conclusions:** Prenatal maternal smoking was associated with DNA methylation signatures in 39 saliva samples, a clinically practical tissue. Polymethylation scores for prenatal maternal 40 smoking were portable across genetic ancestries and more accurate than individual DNA 41 methylation sites. DNA polymethylation scores from saliva samples could serve as robust and 42 practical clinical biomarkers of prenatal maternal smoke exposure.

43 Keywords

44 DNA methylation, prenatal maternal smoking, salivary biomarker, longitudinal cohort

45 Background

46 Maternal prenatal smoking is a public health concern. Children exposed to cigarette smoking in 47 utero are more likely to have low-birth weight, negative neurodevelopmental outcomes, and 48 asthma [1]. In 2018, 11% of pregnant women in the United States aged 15-44 reported any past-49 month cigarette use [2]. Measuring prenatal maternal smoking behavior is challenging. Maternal 50 prenatal smoking is underreported due to stigma [3, 4]. The gold-standard for smoking 51 measurements, serum cotinine levels, have a half-life of nine hours in pregnant women, limiting 52 the ability for accurate detection to a short window [5]. Further, serum cotinine measures during 53 pregnancy are rarely available outside of birth cohorts, limiting clinical application as a marker 54 of prenatal exposures. Developing a portable and reliable biomarker of prenatal maternal smoke 55 exposure would have important implications for research and clinical practice. 56 In infant cord blood and placental tissues, maternal cigarette smoking during pregnancy is 57 associated with reproducible DNA methylation signatures, though this has primarily been tested 58 in European cohorts [6–8]. Prenatal maternal cigarette smoking exposure is associated with 59 postnatal DNA methylation signatures in blood from cohorts of older children and adults [9, 10]. 60 Few studies have considered the persistence of the association between maternal prenatal 61 cigarette smoking and DNA methylation at different ages in the same individuals. Additionally, 62 little work has considered the portability of the association between maternal prenatal cigarette 63 smoking and DNA methylation outside of cord blood and placental tissue. DNA methylation 64 drives cell differentiation and cell type proportions differ across tissue types. Epigenetic markers

of prenatal maternal smoking are known to differ between cord blood and placental samples [7].
Cord blood and placental samples are unlikely to be available in clinical settings. While
peripheral blood is a more realistic clinical sample, saliva is even easier to collect. To our
knowledge, no study has evaluated associations between maternal prenatal cigarette smoking and
salivary DNA methylation.

70 Additionally, DNA methylation can vary by genetics [11–14], and DNA methylation signatures 71 of own-smoking differ across genetic ancestry groups [15–18]. Only a few studies have 72 examined associations between prenatal maternal cigarette smoking and DNA methylation in 73 non-European ancestry populations. Among 954 infants, 70% of whom had mothers identifying 74 as Black, prenatal maternal smoking was associated with cord blood DNA methylation at 38 75 CpG sites [19]. The direction of the associations between prenatal maternal cigarette smoking 76 and DNA methylation at these sites was generally similar in children of Black and non-Black 77 participants [19]. Among 572 3–5-year-old children, 186 of whom were of African or admixed 78 genetic ancestry, prenatal maternal smoking was associated with DNA methylation in peripheral 79 blood samples, but ancestry-stratified analyses were not performed [20]. Similarly, among 89 80 middle-aged women, of whom 28 reported African American or Hispanic ethnicity, prenatal 81 maternal cigarette smoking was associated with DNA methylation at 17 of 190 tested CpG sites 82 [9]. Adjusting for ancestry did not substantially affect the association between prenatal maternal 83 smoking and DNA methylation at any of the sites, although the authors note that African 84 American women had on average 2–5% higher mean DNA methylation on the absolute scale as 85 compared with White and Hispanic women at 5 CYP1A1 CpG sites [9]. Of 148 CpG sites 86 selected based on their association with prenatal maternal smoking among primarily European 87 children, 7 CpG sites were also associated with prenatal maternal cigarette smoking in a cohort

88 of 572 Latino children [6, 21]. While prenatal maternal cigarette smoking is associated with 89 DNA methylation, the consistency of this association across genetic ancestry is understudied. 90 After association testing, an important next step is to evaluate DNA methylation as a biomarker 91 of prenatal maternal smoke exposure by comparing DNA methylation-based classification of 92 maternal smoking behavior to self-reported behavior. Biomarkers can consist of single DNA 93 methylation sites or summary measures across multiple sites [17]. One option is a 94 polymethylation score, analogous to a polygenic score. In the polymethylation score, CpG sites 95 are weighted by the strength of their association with maternal smoking from a previous, 96 independent sample and then summed to a single score [24, 25]. One such DNA methylation 97 score calculated from cord blood classified maternal smoking behavior with an area under the 98 curve (AUC) of 0.82 in a primarily European cohort [23]. Among 572 3–5-year-old children, 99 186 of whom were of African or admixed ancestry, prenatal maternal smoking behavior was 100 classified with an AUC of 0.87 [20]. Among middle-aged adults, a score calculated using DNA 101 methylation in peripheral blood samples from a single time point could even predict prenatal 102 smoke exposure (30 years previously) with an AUC of 0.72 (95% confidence interval 0.69, 0.76) 103 [10]. Ideally, a biomarker for prenatal maternal smoking would be consistent over the life course 104 and portable across genetic ancestry groups. However, the consistency of DNA methylation as a 105 biomarker for prenatal maternal smoking across age, tissue, and genetic ancestry has not been 106 evaluated in the same study.

DNA methylation differences hold promise as a biomarker for prenatal maternal smoking.
Before translation to clinical applications, we must understand how and if the signal varies
across age, tissue sample, and genetic ancestry. In the Fragile Families and Child Wellbeing

110 study, a diverse longitudinal birth cohort of children, we aimed to assess the potential of salivary

DNA methylation biomarkers for prenatal maternal cigarette smoking. We tested associations
between prenatal maternal smoke exposure and saliva DNA methylation, including
polymethylation scores for smoke exposure, individual *a priori* CpG sites, global DNA
methylation, and epigenetic clocks. We then performed age- and ancestry-stratified analyses to
test the hypothesis that DNA methylation could serve as a persistent and consistent biomarker of
prenatal maternal smoking.

117 **Results**

118 Study sample descriptive statistics

119 In a sample of the Fragile Families and Child Wellbeing Study, saliva DNA methylation was 120 measured on 1806 samples from 897 unique participants with the Illumina 450K array. Complete 121 data on covariates of interest was available on 1499 samples from 809 participants who were 122 included in the analysis (Figure 1). There were 690 participants with both age 9 and age 15 DNA 123 methylation samples. Excluded samples were similar to included samples, except that included 124 samples were slightly more likely to be from children of African genetic ancestry and less likely 125 to be from children of Hispanic genetic ancestry (Supplemental Table 1). In the included sample, 126 20% percent of the mothers reported any prenatal maternal smoking, 12% reported prenatal 127 alcohol use and 5% reported prenatal drug use. The mean income to poverty ratio of mothers at 128 birth was 2.2. Of the children in the analytic sample, 50% were male, 60% were of African 129 genetic ancestry, and 24% were of Hispanic genetic ancestry.

130 We calculated several summary measures of DNA methylation, including polymethylation

131 scores for smoke exposure, global DNA methylation, and epigenetic clocks. Many of the

132 methylation summary measures were correlated with each other (Supplemental Figure 1). For

133 example, as expected, the percent of estimated immune cells was perfectly inversely correlated 134 with the percent of estimated epithelial cells (Pearson ρ =-1; P value<0.0001). Our 135 polymethylation score for prenatal smoke exposure, which was calculated using coefficients 136 from a cell-type corrected regression, was weakly correlated with estimated cell-type proportion 137 of immune cells (Pearson $\rho=0.05$; *P* value=0.04). 138 We compared epigenetic measures between the age 9 and age 15 visits among the 690 139 individuals with data from both visits (Supplemental Figure 2). The correlation across ages was 140 strongest for the polymethylation score for prenatal smoke exposure (Pearson $\rho=0.9$, P 141 value<0.0001). Global DNA methylation (0.5, P value<0.0001) and epigenetic clocks were less 142 strongly correlated across ages (Pediatric: 0.51; P value<0.0001, GRIM: 0.47; P value<0.0001) 143 The distribution of epigenetic ages shifted higher between the age 9 and age 15 visits, as 144 expected (Supplemental Figure 3). The pediatric clock more closely reflected chronological age 145 than the GRIM clock. Among age 9 samples, the mean estimated age from the pediatric clock 146 was 9 and the mean estimated age from the GRIM clock was 25. Among age 15 samples, the 147 mean estimated age from the pediatric clock was 12 and the mean estimated age from the GRIM 148 clock was 30. The distribution of estimated cell-type proportions also shifted between visits 149 while the distribution of global methylation and polymethylation scores were more consistent 150 (Supplemental Figure 3). 151 In bivariate analyses and multivariable models, we focused on the polymethylation score for 152 prenatal smoke exposure and the single top CpG site from prior research, cg05575921 in the 153 AHRR gene, as hypothesized biomarkers, and used global methylation and the pediatric clock as

154 negative controls.

Bivariate associations between prenatal maternal smoking and DNA methylation summary measures

157	Mothers who reported smoking during pregnancy had lower income-to-poverty ratios (1.49) than
158	those who did not (2.38). Mothers who smoked were more likely to report prenatal alcohol use
159	(30% vs 7%), prenatal drug use (18% vs 2%) and postnatal smoking (96% vs 26%) than mothers
160	who did not report prenatal maternal smoking (Table 1). Children of mothers who reported
161	smoking during pregnancy were more likely to be of European genetic ancestry (23%) than
162	children of mothers who did not (14%, P value=<0.001). Children of mothers who reported
163	smoking during pregnancy had higher prenatal maternal smoking polymethylation scores than
164	children of mothers who did not at both the age 9 (mean-centered scores of 0.08 vs -0.04, P
165	value<0.001) and age 15 (0.11 vs -0.01, <i>P</i> value<0.001) visits (Table 1, Supplemental Table 2).
166	At age 9, children exposed to prenatal maternal smoking had lower DNA methylation at
167	cg05575921 (76.82%) than children of non-smoking mothers (77.81%, <i>P</i> value=0.05). At age
168	15, children exposed to prenatal smoking had lower DNA methylation at cg05575921 (76.13%)
169	than children of non-smoking mothers, although this difference was not significant (76.82% P
170	value=0.24). Epigenetic age from the pediatric and GRIM clocks and global DNA methylation
171	did not differ between children exposed vs unexposed to prenatal maternal smoking.

172 Multivariable associations between prenatal maternal smoking and DNA methylation

173 summary measures

174 The association between prenatal maternal smoking and the polymethylation score for prenatal 175 smoke exposure was also observed in multivariable models, adjusting for base model covariates 176 of child sex, maternal income to poverty ratio at baseline, indicator variable for city of residence

177 being Detroit, Chicago or Toledo, proportion of salivary immune cells, sample plate from DNA 178 methylation analysis, child age and the first two principal components of genetic ancestry 179 (Figure 3; Supplemental Table 3). At age 9, prenatal maternal smoke exposure was associated 180 with a 0.52 (95% CI: 0.36, 0.67) standard deviation higher polymethylation score for prenatal 181 smoke exposure. At age 15, prenatal maternal smoke exposure was associated with a 0.46 182 (95%CI: 0.3, 0.62) standard deviation higher prenatal smoke exposure polymethylation score for 183 prenatal smoke exposure. A consistent association was observed when stratifying by genetic 184 ancestry. In the African genetic ancestry sample (n = 488) at age 9, prenatal maternal smoking 185 was associated with a 0.55 (95% CI: 0.35, 0.75) standard deviation higher polymethylation score 186 for prenatal smoke exposure. The direction of the association was similar in the European and 187 Hispanic genetic ancestry samples, though the effect size was slightly attenuated and no longer 188 statistically significant (Figure 3; Supplemental Table 4). 189 At age 9, prenatal maternal smoking was associated with 1 percent lower DNA methylation at 190 cg055975921 (95%CI: -1.65, -0.34) after adjusting for base model covariates. Similarly, at age 191 15 prenatal maternal smoking was associated with 0.8 percent lower DNA methylation at 192 cg055975921 (95%CI: (-1.58, -0.02)). Prenatal maternal smoking remained significantly 193 associated with a decrease in cg05575921 DNA methylation in the African genetic ancestry 194 sample at age 9 (-1.3 (95%CI: -2.15, -0.46)) although the association was not significant at age 195 15 (-0.97 (95% CI: -1.98, 0.04); Figure 3). In the European genetic ancestry sample, the 196 association was consistent in direction at age 9 (-0.81 (95%CI: -2.45, 0.82)) and age 15 (-1.79 197 (95% CI: -3.43, -0.15)). In the Hispanic genetic ancestry sample, the association was no longer 198 significant and not consistent in direction (Age 9: -0.05 (95%CI: -1.69, 1.59); Age 15: 0.82

199 (95%CI: -1.28, 2.92)) (Figure 3).

200 Prenatal maternal smoking was not associated with global DNA methylation or epigenetic age201 (Figure 3).

202 Sensitivity analyses for association testing

203 After additionally adjusting for other prenatal exposures and postnatal smoke exposure, the 204 association between prenatal maternal smoking and the polymethylation score was robust 205 (Supplemental Figure 4). Similarly, after adjusting for other prenatal exposures and postnatal 206 smoke exposure, the direction of the association between prenatal maternal smoking and cg055975921 was consistent, although no longer significant at age 15. Very few children who 207 208 were exposed to maternal smoking prenatally were unexposed to postnatal smoke (Supplemental 209 Figure 5). However, children exposed only to postnatal smoke did not have higher 210 polymethylation scores than children unexposed to both postnatal and prenatal smoke 211 (Supplemental Figure 5). Results from linear mixed effect models were similar to age-stratified 212 and base covariate adjusted linear models (Supplemental Tables 3 & 4). Results were also 213 similar when controlling for surrogate variables instead of known covariates (Supplemental 214 Figures 4 and 6; Supplemental Table 5). 215 Results were also similar when using polymethylation scores constructed with alternative

regression coefficients (see Methods, Supplemental Figure 7). For our main analysis we used coefficients from a regression of sustained smoking exposure and DNA methylation in newborn cord blood with cell-type control. As sensitivity analyses, we used coefficients from regressions of: sustained smoking exposure and DNA methylation in newborn cord blood without cell-type control, sustained smoking exposure and DNA methylation in peripheral blood from older children without cell-type control, and any smoking exposure and DNA methylation in newborn

cord blood without cell-type control [6]. The association between prenatal maternal smoking and
 the polymethylation score using regression coefficients from newborn cord blood with cell-type
 controls was the strongest.

In addition to cg055975921 in the AHHR gene, we tested the association of four other a priori

probe sites identified from previous meta-analyses. We replicated the association of prenatal

227 maternal smoking with these CpG sites (Supplemental Table 2, Supplemental Figure 8).

228 Accuracy of polymethylation scores as a biomarker of prenatal maternal smoking

229 Next, we compared the accuracy of different DNA methylation summary measures for

230 classifying prenatal maternal smoking using receiver operating curves (Figure 4A; Supplemental

Table 6). We estimated classification of prenatal maternal smoking when using DNA

232 methylation summary measures alone. We also estimated prenatal maternal smoking

233 classification when using DNA methylation summary measures in addition to base model

234 covariates (child sex, maternal income to poverty ratio at baseline, child age at DNA methylation

235 measurement, indicator variable for city of residence being Detroit, Chicago or Toledo,

estimated immune cell proportion, plate from methylation processing and the first two genetic

237 principal components). When used without DNA methylation measures, these base model

variables had an area under the curve (AUC) of 0.73 at age 9 and 0.72 at age 15.

At age 9, including the polymethylation score for prenatal smoke exposure significantly

improved the base model covariates classification (AUC: 0.78, *P* value comparing to base

241 model<0.001). At age 15, similarly, including the polymethylation score for prenatal smoke

242 exposure significantly improved the base model covariates classification (AUC:0.77, P

243 value<0.001).

At age 9, the base model covariates with the polymethylation score for prenatal smoke exposure

- had a larger AUC than the base model covariates with cg05575921 (AUC base model covariates
- 246 + cg05575921: 0.74; P value =0.02). At age 15, this was also true (AUC for base model
- covariates + cg05575921=0.73, *P* value=0.01; Supplemental Table 6). Accurate classification
- 248 was not improved by including polymethylation scores from age 9 and age 15 together (Figure

249 4B).

250 Sensitivity analyses for biomarker accuracy assessment

251 Classification of prenatal maternal smoke exposure when using other coefficients as the weights

- in construction of the polymethylation scores was similar to the results when using coefficients
- 253 from cell-type controlled regressions of sustained prenatal maternal smoking and DNA
- 254 methylation in cord blood (Supplemental Table 7).

255 **Discussion**

256 In the longitudinal Fragile Families and Child Wellbeing birth cohort, we observed that prenatal 257 maternal smoking was associated with several characterizations of DNA methylation in 258 children's saliva samples from ages 9 and 15. Prenatal maternal smoking was associated with 259 polymethylation scores for prenatal smoke exposure across strata of both child age and genetic 260 ancestry. Global methylation and epigenetic clocks were not associated with maternal smoking 261 exposure. Polymethylation scores for prenatal smoke exposure had reasonable accuracy for 262 classifying prenatal maternal smoking (AUC > 0.7). Classification when using polymethylation 263 scores for prenatal maternal smoke exposure was better than when using a single *a priori* CpG 264 site, cg05575921 in the AHRR gene.

Our findings are consistent with the previous literature on associations between prenatal maternal smoking and DNA methylation. We replicated the top hit from a previous epigenome wide association analysis [6]. Further, we found evidence of association in several additional hits from epigenome wide association studies of DNA methylation in cord and peripheral blood [6, 26]. There are no previous studies of prenatal maternal smoking and saliva DNA methylation. However, previous work has shown that the majority of CpG sites are similarly methylated in

blood and saliva (reviewed in [27]).

272 We advance prenatal smoking - DNA methylation literature by evaluating the persistence of the 273 association between prenatal maternal smoking and DNA methylation as children age and its 274 portability across tissue and ancestry. Polymethylation scores built using coefficients from meta-275 analysis of cord blood DNA methylation from primarily European-ancestry newborns were still 276 associated with prenatal maternal smoking in our independent saliva samples from a diverse 277 cohort at ages 9 and 15 [6]. The portability of other risk scores, such as polygenic risk scores, 278 across genetic ancestries is a complex research area [28] and the portability of epigenetic 279 summary measures has been identified as a key area for evaluation [29]. In this case, the 280 polymethylation score for prenatal maternal smoking appears to be portable across genetic 281 ancestry groups. Effect estimates were consistent across ancestries at age 9, although Hispanic 282 and European genetic ancestry samples had lower, non-significant effect estimates at age 15. The 283 decreased precision may be the result of the reduced sample size of the Hispanic and European 284 genetic ancestry samples. The reduction in effect estimate magnitude could reflect higher 285 unreported smoking initiation in European and Hispanic ancestry teens in the United States than 286 African ancestry teens. Genetic ancestry correlates with race, and White and Latino teens have 287 much higher rates of teen smoking and earlier ages at initiation than Black children [30]. Though

we excluded children who reported own-smoking from our analytic sample, under-reporting of
own-smoking could influence DNA methylation at age 15, creating outcome misclassification.
This could also explain the observed attenuation of the effect on *AHRR*:cg05575921 methylation
by age 15 in our sample, as DNA methylation at this probe is known to vary by personal
cigarette smoking [22, 31].

293 Our findings are also consistent with previous work on DNA methylation as a biomarker for 294 prenatal maternal smoke exposure. Prenatal maternal smoking classification using saliva DNA 295 methylation in our sample of 9- and 15-year-olds performed comparably to classification using 296 peripheral blood from older adults (AUC 0.72) [10]. However, previous prenatal maternal smoke 297 exposure biomarkers created using LASSO regression and cord blood from newborns performed 298 better (AUCs ranging from 0.82-0.97) [20] A support vector machine approach performed on 299 peripheral blood from 3–5-year-old children also more accurately classified prenatal maternal 300 smoke exposure (AUC=0.87) [23]. Differences in DNA methylation patterns across tissues and 301 over time may influence the performance of DNA methylation biomarkers. Different methods 302 for summarizing across multiple DNA methylation sites may also influence biomarker 303 performance. The similarity in performance between saliva DNA methylation in our study and 304 peripheral blood DNA methylation in older adults is encouraging for the use of saliva as a 305 readily accessible clinical sample.

306 Our analysis contributes to the development of an accurate methylation biomarker for prenatal 307 maternal smoking by evaluating the impact of specific methodological choices on accuracy of 308 classification. DNA methylation biomarkers may be especially susceptible to confounding by 309 subject age at methylation measurement and cell-type proportion [29]. Prenatal maternal smoke 310 exposure classification accuracy of polymethylation score was similar when using coefficients

from cord blood vs peripheral blood samples from older children. Classification accuracy was not improved by using two time-points of methylation measurement. Classification accuracy was improved when polymethylation scores used coefficients which incorporated cell-type control. Our analysis therefore suggests that cell-type control when both generating (in the epigenome wide association study) and applying coefficients for polymethylation scores may positively influence outcome classification accuracy, although more work comparing coefficients from different populations is still needed.

318 Our analysis suggests that polymethylation scores may be more accurate than using single CpG 319 sites as biomarkers. The site cg05575921 in the AHRR gene is a consistent marker of prenatal 320 maternal smoke exposure in meta-analyses of newborn cord blood [6]. DNA methylation at 321 cg05575291 in the AHRR gene can accurately classify own-smoking behavior in both blood 322 (area under the curve 0.995) and saliva (area under the curve 0.971) [22, 31]. However, salivary 323 AHRR:cg05575921 was not a persistent marker of prenatal maternal smoking in an analysis of 324 middle-aged adult women [10]. In our sample, salivary AHRR:cg05575921 methylation was less 325 accurate at predicting prenatal maternal smoke exposure than polymethylation scores. The 326 accuracy of AHRR:cg05575921 and other single CpG site biomarkers may be influenced by 327 time-since-exposure and new environmental exposures. Incorporating information across 328 multiple sites of DNA methylation may yield a biomarker more robust to these influences. 329 Our analysis is not without its limitations. We used maternal self-report of prenatal maternal smoke exposure, as serum cotinine levels were not available. Due to social desirability bias, this 330 331 could result in exposure misclassification. We would expect this to bias our results towards the 332 null. In any analysis of a prenatal exposure and postnatal outcome, there is the possibility of 333 selection bias into the cohort due to live birth bias. Selection bias is also possible due to loss-to-

follow-up between birth and age 15. Additionally, while we controlled for postnatal secondhand smoke exposure and excluded children who reported any own-smoking, we cannot exclude the possibility of residual confounding in this observational cohort.

337 However, our analysis also has several strengths. We analyzed samples from a large cohort of 338 diverse participants underrepresented in genetic and epigenetic research [32, 33]. While our 339 exposure measurement of prenatal maternal smoking was self-reported, it was assessed 340 prospectively and preceded outcome measurements. We analyzed repeated measures of DNA 341 methylation with reproducible array measures conducted in a single batch. We tested 342 associations between prenatal maternal smoking and multiple DNA summary measures to 343 evaluate the specificity of the polymethylation scores. In sensitivity analyses, we adjusted for 344 other prenatal exposures and postnatal smoke exposure to examine the specificity of the 345 biomarker to nature and timing of exposure.

346 Conclusions

347 In a large, prospective study of diverse participants, we showed that DNA methylation in 348 children's saliva had strong associations with and reasonable classification accuracy for prenatal 349 maternal smoke exposure. Further, we demonstrated that polymethylation scores could be 350 applied as a biomarker of prenatal maternal smoke exposure across genetic ancestry groups, an 351 important consideration for the equitable biomarker development. The development and 352 application of biomarkers for prenatal maternal smoke exposure has important implications for 353 epidemiological research and clinical practice. Given the difficulty of measuring prenatal 354 maternal smoke exposure, such a biomarker could allow for confounder control in research areas 355 where such control is currently impossible. Prenatal maternal smoke exposure is prevalent and

has negative health consequences, thus an exposure biomarker could be used to provide supportand health interventions for children.

358 Methods

359 Cohort

360 The Fragile Families and Child Wellbeing Study is a birth cohort of nearly 5,000 children born 361 in 20 cities in the United States between 1998 and 2000 [34]. Participants were selected at 362 delivery using a three-stage stratified random sample design which oversampled unmarried 363 mothers by a ratio of 3:1 [34]. Participants were excluded on the following criteria: those with 364 parents who planned to place the child for adoption, those where the father was deceased, those 365 who did not speak English or Spanish well enough to be interviewed, births where the mothers or 366 babies were too ill to complete the interview, and those where the baby died before the interview 367 could take place. Children were followed longitudinally with assessments at ages 1, 3, 5, 9 and 368 15; additional follow up is ongoing. Assessments included medical record extraction, biosample 369 collection, in-home assessments, and surveys of the mother, father, primary caregiver, teacher 370 and child. At ages nine and fifteen a saliva sample was taken from the child [34]. A subsample of 371 the Fragile Families cohort was selected for saliva DNA and DNA methylation processing. To be 372 eligible for the DNA methylation assessment children had to have participated and given saliva 373 at age 9 and 15; after which a random sample of these eligible participants was then selected. 374 One exception to this rule is that all participants in the Study of Adolescent Neurodevelopment 375 (SAND) were assayed even if they only provided a sample at one time-point. All analyses 376 account for this oversample of these participants.

377 Covariates and exposure measurement

- 378 Demographic and prenatal maternal substance use variables were derived from maternal self-
- 379 report questionnaire data at baseline (child's birth).
- 380 Maternal covariates included maternal income to poverty ratio at baseline, prenatal smoking,
- 381 prenatal maternal drug and alcohol use, and postnatal maternal or primary caregiver smoking.
- 382 Maternal income to poverty ratio is a constructed variable of the ratio of total household income
- 383 (as self-reported by the mother) to the official poverty thresholds designated by the United States
- 384 Census Bureau for the year preceding the interview. At baseline, mother's answered categorical
- 385 questions about their prenatal smoking, drug, and alcohol use. For maternal prenatal smoking,
- 386 mothers were asked
- 387 During your pregnancy, how many cigarettes did you smoke? Did you smoke...:
- 388 2 or more packs a day
- 389 1 or more but less than 2 packs per day
- 390 Less than 1 pack a day
- 391 None
- 392 Few participants reported smoking a pack or more a day, thus we dichotomized to any vs no
- 393 prenatal maternal smoking. For maternal prenatal drug and alcohol use the mothers were asked
- 394 During your pregnancy how often did you use drugs/drink alcohol (respectively):
- 395 Never
- 396 Less than 1 time per month
- 397 Several times per month

398 Several times per week

399 Every day

When the child was 1, 5, 9 and 15 years of age, primary caregivers responded to questions about maternal and in-home smoking. To encapsulate general early childhood smoke exposure, we created a binary variable for postnatal exposure at ages 1 or 5. To encapsulate recent postnatal smoke exposure, we used a categorical variable for packs per day (no smoking, less than one pack/day, one or more packs/day) in the month prior to the age 9 and 15 interview. To control for the oversampling of the Detroit, Toledo and Chicago locations, an indicator variable denoting residence in one of these three cities was created.

407 Child covariates included child sex, child report of personal cigarette smoking, and child genetic 408 ancestry. Mothers reported sex (male/female) of their child at baseline. At ages 9 children were 409 asked if they had ever smoked a cigarette or used tobacco (yes/no) and at age 15 they were asked 410 if they had ever smoked an entire cigarette (yes/no).

411 Child genetic ancestry was calculated. Grants R01 HD36916, R01 HD073352, and R01

412 HD076592 provided support for the collection, assay, and analysis of the genetic data in the

413 Fragile Families cohort. Principal components (PC) of child genetic ancestry were calculated

414 from genetic data using Illumina PsychChip_v1-1 with child saliva samples. Genetic ancestry

415 was assigned by comparing PC loadings to 1000 Genomes super population clusters. Samples

416 with PC1 > 0.018 and PC2 > -0.0075 were assigned to European ancestry. Samples with PC1 < -

417 0.005 and PC2 > 0.007+0.75(PC1) were assigned to African ancestry. Samples with PC1 > 0.018

418 and -0.055 < PC2 < 0.025 were assigned to Hispanic ancestry [35].

419 **DNA methylation measurement**

420 Salivary samples from the children were collected at ages nine and fifteen using the 421 Oragene•DNA sample collection kit (DNA Genotek Inc., Ontario). Saliva DNA was extracted 422 manually using DNA Genotek's purification protocol using prepIT L2P. DNA was bisulfite 423 treated and cleaned using the EZ DNA Methylation kit (Zymo Research, California). Samples 424 were randomized and plated across slides by demographic characteristics. Saliva DNA 425 methylation was measured using the Illumina HumanMethylation 450k BeadArray [36] and 426 imaged using the Illumina iScan system. All samples were run in a single batch to minimize 427 technical variability. 428 DNA methylation image data were processed in R statistical software (3.5) using the minfi 429 package [37]. The red and green image pairs (n=1811) were read into R and the minfi 430 *preprocessNoob* function was used to normalize dye bias and apply background correction. 431 Further quality control was applied using the ewastools packages [38]. We dropped samples with 432 >10% of sites have detection p-value >0.01 (n=43), sex discordance between DNA methylation 433 predicted sex and recorded sex (n=20), and abnormal sex chromosome intensity (n=3). CpG sites 434 were removed if they had detection p-value >0.01 in 5% of samples (n=26,830) or were 435 identified as cross-reactive (n=27,782) (Figure 1) [39]. We used the November 2021 data freeze 436 of the Fragile Families and Child Wellbeing DNA methylation data. Relative proportions of 437 immune and epithelial cell types were estimated from DNA methylation measures using a 438 childhood saliva reference panel [40].

439 We created polymethylation scores for prenatal maternal smoke exposure. From an independent

440 meta-analysis of prenatal smoke exposure and newborn DNA methylation, we extracted the

441 regression coefficients of 6,074 CpG sites associated with prenatal maternal smoking at a false

442	discovery ratio corrected P value <0.05 [6]. We mean-centered the DNA methylation beta values
443	in our study, weighted them by the independent regression coefficients and took the sum. We
444	calculated polymethylation scores using regression coefficients from 4 different regressions. For
445	our main analysis we used coefficients from a regression of sustained smoking exposure and
446	DNA methylation in newborn cord blood with cell-type control. As sensitivity analyses, we used
447	sustained smoking exposure and DNA methylation in newborn cord blood without cell-type
448	control, sustained smoking exposure and DNA methylation in peripheral blood from older
449	children, any smoking exposure and DNA methylation in newborn cord blood) [6].
450	Global DNA methylation was calculated for each sample as the mean methylation value of each
451	sample across the cleaned probe set. Mean DNA methylation restricted to probes in genomic
452	regions (CpG island, shore, shelf or open sea, as identified in the R package
453	IlluminaHumanMethylation450kanno.ilmn12.hg19 v 0.6.0) was also calculated.
454	Pediatric epigenetic age was calculated for each sample using the coefficients and methods
455	provided by the creators (see <https: github.com="" kobor-lab="" public-scripts="">) [41]. The GRIM</https:>
456	age clock, including the smoking pack-years sub-scale, was calculated as previously described
457	[42].
458	Single a priori CpG sites were selected from previous large meta-analyses of prenatal maternal
459	smoking and DNA methylation in children's cord and peripheral blood samples [6, 26].
460	Surrogate variables were calculated from DNA methylation data using the function sva from the
461	R package sva version 3.38.

462 Statistical analyses

463 Inclusion exclusion criteria

464 From the 1685 samples from 882 unique individuals with quality-controlled DNA methylation 465 data, we further excluded any samples missing data on: maternal prenatal smoking (0 samples), 466 alcohol (4 samples) or other drug use (6 samples), maternal income to poverty ratio (0 samples), 467 maternal postnatal smoking data (105 samples). We also excluded samples with missing child 468 sex (0 samples), child age (0 samples) or genetic data (22 samples). Finally, if a child reported 469 ever smoking a cigarette or using tobacco age 9, we excluded all of their available samples. Age 470 15 samples from children who reported ever smoking a cigarette at age 15 were also excluded. 471 Children who were missing a response to the question at age 9 but answered that they had never 472 smoked a whole cigarette at age 15 were kept in the sample.

473 Base model

474 In our base model we adjusted for maternal income to poverty ratio at baseline, child sex, child 475 age, an indicator variable for residence in Detroit, Chicago or Toledo, plate from DNA 476 methylation processing, and estimated immune cell proportion estimated from DNA methylation. 477 In nonstratified models, we adjusted for the first two components of genetic ancestry from 478 principal component analysis. In ancestry-stratified models, the first two principal components 479 from principal component analysis run within each ancestry strata were used. While child sex, 480 child age, plate from DNA methylation processing and immune cell proportions are not 481 confounders (as they cannot casually affect prenatal maternal smoke exposure), these variables 482 can strongly affect DNA methylation and so were adjusted for as precision variables.

483 Receiver operator curve analysis

484	To evaluate the accuracy of the DNA methylation summary measures as biomarkers of prenatal
485	maternal smoking, we used a receiver operating curve. First, we regressed exposure to prenatal
486	maternal smoking (outcome) against the DNA methylation summary measures in individual
487	logistic regressions, while adjusting for the base model variables listed above. Next, we
488	calculated receiver operating curves (ROC) and area under the curves (AUCs) using the function
489	roc from the R library pROC version 1.18.0. We compared ROC curves and AUC using the
490	Delong method and the function roc.test from the R library pROC version 1.18.0.
491	Sensitivity analyses
492	In sensitivity analyses we performed additional adjustments: 1) models adjusting for prenatal
493	drug and alcohol use, 2) models adjusting for prenatal drug and alcohol use and postnatal
494	maternal/primary caregiver smoking, 3) models adjusting for surrogate variables calculated from
495	DNA methylation data.
496	In addition to the cross-sectional models within visit-strata, we performed a linear mixed effect
497	model with a random intercept for child.
498	Code to perform all analyses is available (www.github.com/bakulskilab)

499 **Declarations**

500 Ethics approval and consent to participate

- 501 Participants provided written informed consent for the study. The data used in this manuscript
- 502 were prepared by the Fragile Families and Childhood Wellbeing Study administrators following

- 503 approval of the manuscript proposal. These secondary data analyses were approved by the
- 504 University of Michigan Institutional Review Board (IRB, HUM00129826)
- 505 **Consent for publication**
- 506 Not applicable
- 507 Availability of data and materials
- 508 Many of the variables used in this analysis are publicly available in the Fragile Families dataset.
- 509 Some of the data used in this analysis, including genetic and epigenetic data, is restricted use but
- 510 available to researchers upon reasonable application.
- 511 Competing interests
- 512 The authors have no competing interests to declare.

513 **Funding**

- 514 This research was made possible through several grants (Fragile Families Core Data Collection:
- 515 R01 HD036916, genetic data processing R01 HD036916, R01 HD073352, R01 HD076592 and
- 516 R01 MD011716). In addition, FB was supported by the National Institutes of Health National
- 517 Institute of Dental and Craniofacial Research (F31 DE029992), EB was supported by R01
- 518 AG055406 and R01 AG067592, and CM was supported by R01 AG071071. KB and JD were
- supported by R01 AG067592 (MPI: Bakulski, Ware), R01 ES025531 (PI: Fallin), R01
- 520 ES025574 (PI: Schmidt), and R01 MD013299 (PI: Hicken).

521 Authors' contributions

- 522 FB performed the analysis with contributions from JD, JF, and EW. FB and KB wrote the paper
- 523 with all authors contributing to revisions. CM, DN and LS contributed to the design and
- 524 processing of the DNA methylation data subcohort. DN, CM, KM, EW, and FB all contributed
- 525 to the design and conception of the analytic plan. All authors reviewed and revised the
- 526 manuscript.

527 Acknowledgements

- 529
- 530 Table 1: Bivariate associations between prenatal maternal smoke exposure and selected DNA
- 531 methylation summary measures and important covariates among a diverse sample of 809
- 532 children in the Fragile Families and Child Wellbeing study

Characteristic

Age 15

⁵²⁸ Not applicable

		Not exposed,	Smoke exposed,	-		Not exposed,	Smoke exposed,	
	Ν	$N = 598^{1}$	$N = 155^{1}$	p-value ²	Ν	$N = 603^{1}$	$N = 143^{1}$	p-valu
Child characteristics								
Polymethylation score for smoke exposure*	753	-0.04 (0.22)	0.08 (0.22)	<0.001	746	-0.01 (0.22)	0.11 (0.23)	<0.00
AHRR gene: percent cg05575921 methylation	753	77.8 (5.2)	76.8 (5.6)	0.047	746	77 (6)	76 (6)	0.2
Pediatric epigenetic clock (years)	753	8.98 (0.75)	8.94 (0.83)	0.6	746	11.62 (1.75)	11.59 (1.70)	0.9
Percent global DNA methylation	753	47.51 (0.74)	47.59 (0.78)	0.3	746	47.48 (0.85)	47.58 (0.83)	0.2
Immune cell proportion (saliva)	753	0.96 (0.10)	0.96 (0.08)	0.4	746	0.92 (0.15)	0.92 (0.14)	>0.9
Epithelial cell proportion (saliva)	753	0.04 (0.10)	0.04 (0.08)	0.4	746	0.08 (0.15)	0.08 (0.14)	>0.9
Ancestry categorization from child principal components of genetic data	753			0.001	746			0.001
African ancestry		355 (59%)	97 (63%)			364 (60%)	88 (62%)	
European ancestry		82 (14%)	35 (23%)			84 (14%)	34 (24%)	
Hispanic ancestry		161 (27%)	23 (15%)			155 (26%)	21 (15%)	
Child gender	753			0.8	746			0.9

			Age 9	Age 15				
		Not exposed,	Smoke exposed,			Not exposed,	Smoke exposed,	
Characteristic	Ν	$N = 598^{1}$	$N = 155^{1}$	p-value ²	Ν	$N = 603^{1}$	$N = 143^{1}$	p-valu
Воу		300 (50%)	76 (49%)			295 (49%)	69 (48%)	
Girl		298 (50%)	79 (51%)			308 (51%)	74 (52%)	
Maternal characteristics								
Maternal prenatal alcohol use	753	44 (7.4%)	47 (30%)	<0.001	746	40 (6.6%)	42 (29%)	<0.00
Maternal prenatal any drug use	753	10 (1.7%)	26 (17%)	<0.001	746	9 (1.5%)	28 (20%)	<0.00
Maternal income to poverty threshold (at baseline)	753	2.41 (2.57)	1.52 (1.56)	<0.001	746	2.41 (2.58)	1.49 (1.57)	<0.00
Maternal city of residence (at baseline)	753			0.12	746			0.6
Detroit, Chicago, or Toledo		148 (25%)	48 (31%)			171 (28%)	44 (31%)	
Not Detroit, Chicago, or Toledo		450 (75%)	107 (69%)			432 (72%)	99 (69%)	
Postnatal maternal smoking at ages 1 or 5	753			<0.001	746			<0.00
No maternal smoking at age 1 and 5		447 (75%)	7 (4.5%)			448 (74%)	7 (4.9%)	
Maternal smoking at age 1 or age 5		151 (25%)	148 (95%)			155 (26%)	136 (95%)	

	Age 9					Age 15			
Characteristic	N	Not exposed, $N = 598^{1}$	Smoke exposed, $N = 155^{I}$	p-value ²	N	Not exposed, $N = 603^{1}$	Smoke exposed, $N = 143^{I}$	p-valu	
Postnatal primary caregiver smoking in past month prior to visit	753			<0.001	746			<0.00	
No smoking		476 (80%)	23 (15%)			511 (85%)	44 (31%)		
Less than pack a day		95 (16%)	85 (55%)			80 (13%)	77 (54%)		
Pack or more a day		27 (4.5%)	47 (30%)			12 (2.0%)	22 (15%)		

Mean (SD); n (%)

Welch Two Sample t-test; Pearson's Chi-squared test

Poylmethylation score constructed using regression coefficients from a model of prenatal maternal smoking and DNA methylation in newborn cord blood as weights. DNA methylat eta values from Fragile Families and Child Wellbeing study were mean-centered, weighted by the regression coefficients and summed.

533			
534			
535			
536			
537			

538 Figure 1 - Selection of samples from the Fragile Families and Child Wellbeing study into

- 539 *analytic subset.* N represents the number of individuals at each step in the selection procedure,
- 540 *M* represents the number of samples. Individuals with repeated measures can have more than
- 541 *one sample.*
- 542 Figure 2 Differences in selected DNA methylation summary measures by self-report of
- 543 prenatal maternal smoking among 809 children in the Fragile Families and Child Wellbeing
- 544 *study at ages 9 and 15.* Samples from children exposed to prenatal maternal smoke in grey,
- 545 samples from children unexposed to prenatal maternal smoke in black. From top-left, clockwise:
- 546 Polymethylation scores for prenatal maternal smoke exposure, constructed using regression
- 547 *coefficients for prenatal smoke exposure predicting DNA methylation in newborn cord blood*
- 548 samples, accounting for cell-type control. DNA methylation values from samples in the Fragile
- 549 *Families and Child Wellbeing study were mean-centered, then multiplied by these regression*
- 550 coefficients and summed. Pediatric epigenetic clock (years). AHRR gene: percent cg05575921
- 551 *methylation. Percent global DNA methylation.* **** *P value*<0.0001 **P value*<0.05, *ns P*
- 552 *value*>0.05

553 Figure 3 - Prenatal maternal smoke exposure is consistently associated with polymethylation

- scores at ages 9 and 15 and is portable across genetic ancestry groups in a sample of 809
- 555 children in the Fragile Families and Child Wellbeing study All models shown controlled for:
- 556 first two principal components of child genetic ancestry (from ancestry-stratified principal
- 557 components for ancestry stratified models), child sex, child age (months), maternal income-to-
- 558 poverty ratio at birth, indicator variable for residence in Detroit, Chicago, or Toledo, immune
- 559 cell proportion estimated from methylation data, yes/no other maternal prenatal drug use, yes/no
- 560 maternal prenatal alcohol use, postnatal maternal smoking when child 1 or 5 years of age,
- 561 *postnatal maternal/primary care give smoking packs/day in month prior to saliva sample.*
- 562 Poylmethylation score constructed using regression coefficients from a model of prenatal
- 563 maternal smoking and DNA methylation in newborn cord blood as weights. DNA methylation
- 564 *beta values from Fragile Families and Child Wellbeing study were mean-centered, weighted by*
- 565 *the regression coefficients and summed. The resulting scores were z-score standardized and used*
- 566 *as outcomes in these models. Red dotted line denotes the null.*

56/ Figure 4 - Polymethylation scores accurately classify prenatal maternal smol	noke exposure al
--	------------------

- 568 ages 9 and 15 among 809 children in the Fragile Families and Child Wellbeing study A)
- 569 *Receiver operator curve for select DNA methylation measures for predicting prenatal smoke*
- 570 *exposure using no other variables (light colors) or using base model variables (dark colors,*
- 571 other variables included: child sex, child age, maternal income-poverty ratio at birth, indicator
- 572 variable for residence in Detroit, Chicago, or Toledo, immune cell proportion and batch of
- 573 *methylation data processing). B) Receiver operator curve for including polymethylation scores*
- 574 *individually at each visit (black & light grey) or jointly at both visits (dark grey).*
- 575 Poylmethylation score constructed using regression coefficients from a model of prenatal
- 576 maternal smoking and DNA methylation in newborn cord blood as weights. DNA methylation
- 577 *beta values from Fragile Families and Child Wellbeing study were mean-centered, weighted by*
- 578 the regression coefficients and summed. The resulting scores were z-score standardized

579

580 **References**

- 581 1. Banderali G, Martelli A, Landi M, Moretti F, Betti F, Radaelli G, Lassandro C, Verduci E
- 582 (2015) Short and long term health effects of parental tobacco smoking during pregnancy and
- 583 lactation: A descriptive review. J Transl Med 13:327
- 584 2. (2019) National survey on drug use and health 2018.
- 585 3. Kvalvik LG, Nilsen RM, Skjærven R, Vollset SE, Midttun O, Ueland PM, Haug K
- 586 (2012) Self-reported smoking status and plasma cotinine concentrations among pregnant women
- 587 in the norwegian mother and child cohort study. Pediatr Res 72:101–7

588	4.	Dietz PM.	Homa D. En	gland LJ. Burl	ev K. Tong	VT. Dube SR	. Bernert JT ((2011)
000				Brown 20, 2001	-,,	,,	,	

- 589 Estimates of nondisclosure of cigarette smoking among pregnant and nonpregnant women of
- reproductive age in the united states. Am J Epidemiol 173:355–9
- 591 5. Dempsey D, Jacob P 3rd, Benowitz NL (2002) Accelerated metabolism of nicotine and
- 592 cotinine in pregnant smokers. J Pharmacol Exp Ther 301:594–8
- 593 6. Joubert BR, Felix JF, Yousefi P, et al (2016) DNA methylation in newborns and maternal
- smoking in pregnancy: Genome-wide consortium meta-analysis. Am J Hum Genet 98:680–696
- 595 7. Everson TM, Vives-Usano M, Seyve E, et al (2021) Placental DNA methylation
- 596 signatures of maternal smoking during pregnancy and potential impacts on fetal growth. Nat
- 597 Commun 12:5095
- 598 8. Cardenas A, Lutz SM, Everson TM, Perron P, Bouchard L, Hivert M-F (2019) Mediation
- 599 by Placental DNA Methylation of the Association of Prenatal Maternal Smoking and Birth
- 600 Weight. American Journal of Epidemiology 188:1878–1886
- 601 9. Tehranifar P, Wu H-C, McDonald JA, Jasmine F, Santella RM, Gurvich I, Flom JD,
- 602 Terry MB (2018) Maternal cigarette smoking during pregnancy and offspring DNA methylation
- 603 in midlife. Epigenetics 13:129–134
- 10. Richmond RC, Suderman M, Langdon R, Relton CL, Davey Smith G (2018) DNA
- 605 methylation as a marker for prenatal smoke exposure in adults. Int J Epidemiol 47:1120–1130
- 606 11. Galanter JM, Gignoux CR, Oh SS, et al (2017) Differential methylation between ethnic
- 607 sub-groups reflects the effect of genetic ancestry and environmental exposures. eLife.
- 608 https://doi.org/10.7554/elife.20532
- 609 12. Fraser HB, Lam LL, Neumann SM, Kobor MS (2012) Population-specificity of human
- 610 DNA methylation. Genome Biology 13:R8

611	13.	Moen EL.	Zhang X	. Mu W	. Delanev	SM.	Wing	C. Mc(Duade J. M	vers J.	Godley	LA.
	10.		, mang is	,	$, \mathbf{D}$ orallo j	~,		\sim, \ldots	2	,	Courte	 ,

- 612 Dolan ME, Zhang W (2013) Genome-Wide Variation of Cytosine Modifications Between
- 613 European and African Populations and the Implications for Complex Traits. Genetics 194:987–
- 614 996
- 615 14. Rahmani E, Shenhav L, Schweiger R, et al (2017) Genome-wide methylation data mirror
- 616 ancestry information. Epigenetics & Chromatin. https://doi.org/10.1186/s13072-016-0108-y
- 617 15. Barcelona V, Huang Y, Brown K, Liu J, Zhao W, Yu M, Kardia SLR, Smith JA, Taylor
- 618 JY, Sun YV (2019) Novel DNA methylation sites associated with cigarette smoking among
- 619 African Americans. Epigenetics 14:383–391
- 620 16. Sun YV, Smith AK, Conneely KN, et al (2013) Epigenomic association analysis
- 621 identifies smoking-related DNA methylation sites in African Americans. Human Genetics
- 622 132:1027–1037
- 623 17. Philibert RA, Beach SRH, Lei M-K, Brody GH (2013) Changes in DNA methylation at
- the aryl hydrocarbon receptor repressor may be a new biomarker for smoking. Clinical
- 625 Epigenetics. https://doi.org/10.1186/1868-7083-5-19
- 626 18. Philibert RA, Beach SRH, Brody GH (2012) Demethylation of the aryl hydrocarbon
- 627 receptor repressor as a biomarker for nascent smokers. Epigenetics 7:1331–1338
- 628 19. Xu R, Hong X, Zhang B, Huang W, Hou W, Wang G, Wang X, Igusa T, Liang L, Ji H
- 629 (2021) DNA methylation mediates the effect of maternal smoking on offspring birthweight: a
- 630 birth cohort study of multi-ethnic US mothernewborn pairs. Clinical Epigenetics.
- 631 https://doi.org/10.1186/s13148-021-01032-6
- 632 20. Ladd-Acosta C, Shu C, Lee BK, et al (2016) Presence of an epigenetic signature of
- 633 prenatal cigarette smoke exposure in childhood. Environ Res 144:139–148

- 634 21. Neophytou AM, Oh SS, Hu D, Huntsman S, Eng C, Rodriguez-Santana JR, Kumar R,
- Balmes JR, Eisen EA, Burchard EG (2019) In utero tobacco smoke exposure, DNA methylation,
- and asthma in latino children. Environmental Epidemiology 3:
- 637 22. Philibert R, Dogan M, Beach SRH, Mills JA, Long JD (2019) AHRR methylation
- 638 predicts smoking status and smoking intensity in both saliva and blood DNA. American Journal
- 639 of Medical Genetics Part B: Neuropsychiatric Genetics 183:51–60
- 640 23. Reese SE, Zhao S, Wu MC, et al (2017) DNA methylation score as a biomarker in
- newborns for sustained maternal smoking during pregnancy. Environ Health Perspect 125:760–
- 642 766
- 643 24. Chen J, Zang Z, Braun U, et al (2020) Association of a Reproducible Epigenetic Risk
- 644 Profile for Schizophrenia With Brain Methylation and Function. JAMA Psychiatry 77:628
- 645 25. Bakulski KM, Fisher JD, Dou JF, Gard A, Schneper L, Notterman DA, Ware EB,
- 646 Mitchell C (2021) Prenatal Particulate Matter Exposure Is Associated with Saliva DNA
- 647 Methylation at Age 15: Applying Cumulative DNA Methylation Scores as an Exposure
- 648 Biomarker. Toxics 9:262
- 649 26. Wiklund P, Karhunen V, Richmond RC, et al (2019) DNA methylation links prenatal
- 650 smoking exposure to later life health outcomes in offspring. Clinical Epigenetics.
- 651 https://doi.org/10.1186/s13148-019-0683-4
- 652 27. Langie SAS, Moisse M, Declerck K, Koppen G, Godderis L, Vanden Berghe W, Drury
- 653 S, De Boever P (2017) Salivary DNA Methylation Profiling: Aspects to Consider for Biomarker
- Identification. Basic & Clinical Pharmacology & Toxicology 121:93–101
- 655 28. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ (2019) Clinical use of
- 656 current polygenic risk scores may exacerbate health disparities. Nature Genetics 51:584–591

- 657 29. Hüls A, Czamara D (2019) Methodological challenges in constructing DNA methylation
- 658 risk scores. Epigenetics 15:1–11
- 659 30. El-Toukhy S, Sabado M, Choi K (2016) Trends in Susceptibility to Smoking by Race and
- 660 Ethnicity. Pediatrics 138:e20161254
- 661 31. Dawes K, Andersen A, Vercande K, Papworth E, Philibert W, Beach SRH, Gibbons FX,
- 662 Gerrard M, Philibert R (2019) Saliva DNA Methylation Detects Nascent Smoking in
- Adolescents. Journal of Child and Adolescent Psychopharmacology 29:535–544
- 664 32. Sirugo G, Williams SM, Tishkoff SA (2019) The Missing Diversity in Human Genetic
- 665 Studies. Cell 177:26–31
- 666 33. Bentley AR, Callier S, Rotimi CN (2017) Diversity and inclusion in genomic research:
- 667 why the uneven progress? Journal of Community Genetics 8:255–266
- 668 34. Reichman NE, Teitler JO, Garfinkel I, McLanahan SS (2001) Fragile families: Sample
- and design. Children and Youth Services Review 23:303–326
- 670 35. Ware EB, Fisher J, Schneper L, Notterman D, Mitchell C (2021) FFCWS polygenic
- 671 scores release 1. Survey Research Center, Institute for Social Research, University of
- 672 Michigan; Department of Molecular Biology, Princeton University
- 673 36. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M
- 674 (2011) Validation of a DNA methylation microarray for 450,000 CpG sites in the human
- 675 genome. Epigenetics 6:692–702
- 676 37. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD,
- 677 Irizarry RA (2014) Minfi: a flexible and comprehensive Bioconductor package for the analysis
- 678 of Infinium DNA methylation microarrays. Bioinformatics 30:1363–1369

- 679 38. Heiss JA, Just AC (2018) Identifying mislabeled and contaminated DNA methylation
- 680 microarray data: an extended quality control toolset with examples from GEO. Clinical
- 681 Epigenetics. https://doi.org/10.1186/s13148-018-0504-1
- 682 39. Chen Y, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, Gallinger S,
- 683 Hudson TJ, Weksberg R (2013) Discovery of cross-reactive probes and polymorphic CpGs in the
- 684 Illumina Infinium HumanMethylation450 microarray. Epigenetics 8:203–209
- 685 40. Middleton LYM, Dou J, Fisher J, et al (2021) Saliva cell type DNA methylation
- reference panel for epidemiological studies in children. Epigenetics 1–17
- 41. McEwen LM, O'Donnell KJ, McGill MG, et al (2019) The PedBE clock accurately
- 688 estimates DNA methylation age in pediatric buccal cells. Proceedings of the National Academy
- 689 of Sciences 117:23329–23335
- 690 42. Lu AT, Quach A, Wilson JG, et al (2019) DNA methylation GrimAge strongly predicts
- 691 lifespan and healthspan. Aging 11:303–327
- 692











